**Name of journal: World Journal of Hepatology**

**ESPS Manuscript NO: 11809**

**Columns: Topic Highlights**

WJH 6th Anniversary Special Issues (5): Hepatitis C virus

**Adiponectin serum level in chronic hepatitis C infection and therapeutic profile**

Peta V *et al*. Adiponectin and chronic hepatitis C

Valentina Peta, Carlo Torti, Natasa Milic, Alfredo Focà, Ludovico Abenavoli

**Valentina Peta, Alfredo Focà**, **Ludovico Abenavoli,** Department of Health Sciences, University Magna Græcia, Campus Germaneto, 88100 Catanzaro, Italy

**Carlo Torti**, Department of Medical and Surgical Sciences, University Magna Graecia, Campus Germaneto, 88100 Catanzaro, Italy

**Natasa Milic**, Department of Pharmacy, University of Novi Sad, 21000 Novi Sad, Serbia

**Author contributions:** Peta V designed the paper, performed research of literature data and wrote the paper; Milic N performed research of literature data; Torti C and Focà A critically revised the paper; Abenavoli L critically revised the paper and drafted the article.

**Correspondence to:** **Ludovico Abenavoli, MD, PhD**, Department of Health Sciences, University Magna Græcia, Campus Germaneto, Viale Europa, 88100 Catanzaro, Italy. l.abenavoli@unicz.it

**Telephone:** +39-0961-3694387 **Fax:** +39-0961-754220

**Received:** June 5, 2014  **Revised:** July 20, 2014

**Accepted:**  November 17, 2014

**Published online:**

**Abstract**

Hepatic steatosis is commonly seen in the patients with chronic hepatitis C virus (HCV) infection. HCV is closely associated with lipid metabolism, and viral steatosis is more common in genotype 3 infection owing to a direct cytopathic effect of HCV core protein. In non-genotype 3 infection, hepatic steatosis is considered largely to be the result of the alterations in host metabolism; metabolic steatosis is primarily linked with HCV genotype 1. Adipose tissue secretes different hormones involved in glucose and lipid metabolisms. It has been demonstrated that adipocytokines are involved in the pathogenesis of non-alcoholic fatty liver disease, as the decreased plasma adiponectin levels, a soluble matrix protein expressed by adipoctyes and hepatocyte, are associated with liver steatosis. Various studies have shown that steatosis is strongly correlated negatively with adiponectin in the patients with HCV infection. The role of adiponectin in hepatitis C virus induced steatosis is still not completely understood, but the relationship between adiponectin low levels and liver steatosis is probably due to the ability of adiponectin to protect hepatocytes from triglyceride accumulation by increasing β-oxidation of free fatty acid and thus decreasing de novo free fatty acid production.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words**: Hepatitis C virus; Adiponectin; Metabolism; Insulin resistance; Hepatitis C virus core protein

**Core tip:** Three main types of steatosis in the patients with hepatitis C virus (HCV) infection are known: a metabolic type associated with metabolic syndrome, viral steatosis directly triggered by the virus and a “middle ground” between metabolic and viral mechanisms. Liver steatosis is a common histological feature of chronic hepatitis C infection, and the recent studies have shown that it is strongly correlated negatively with adiponectin levels. This finding suggests that adiponectin may have a role in modulating the progression of hepatic steatosis in HCV infected patients.

Peta V, Torti C, Milic N, Focà A, Abenavoli L. Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. *World J Hepatol* 2014; In press

**INTRODUCTION**

Hepatitis C virus (HCV) infection is a common liver disease with an estimated 3% of the world’s population chronically infected with this viral pathogen. The majority of the infected individuals (60%-80%) develop chronic hepatitis C (CHC), which is associated with progressive liver fibrosis and a risk of cirrhosis after 20 years[1-3].

About 20%–30% of chronic HCV infections are associated with hepatic steatosis, type II diabetes[4], insulin resistance (IR) and cardiovascular diseases[5]. Hepatic steatosis, defined as an excessive lipid accumulation in the cytoplasm of hepatocytes, is a frequent histological feature in the patients chronically infected with HCV. However, the mechanisms that have induced hepatic steatosis in HCV-infected patients are difficult to understand, due to the possible co-existence of several factors[6]. Different studies have shown that there are three main types of steatosis defined in the HCV patients: metabolic steatosis, viral steatosis and a “middle ground” between metabolic and viral mechanisms[7,8]. The first type has been described in the patients infected with HCV who also suffer from other metabolic disorders such as obesity, dyslipidemia and diabetes mellitus[9]. Metabolic steatosis is primarily linked with HCV genotype 1, but one study has shown the absence of the relationship with viral load and the severity of steatosis in the patients infected by genotype 1[10]. Viral steatosis develops in the absence of other steatogenic co-factors and is linked with HCV genotype 3 infection[11]. In viral steatosis lipid accumulation in hepatocytes may be the result of a direct cytopathic effect of HCV core protein. Different experiments conducted *in vitro* and in transgenic mice, have suggested that the nucleocapsid protein of HCV may be involved in the pathogenesis of triglyceride accumulation in hepatocytes[12,13]. Some other experiments have provided a correlation between the level of intrahepatic HCV genotype 3 ribonucleic acid (RNA) and severity of the steatosis[14] and identified specific “steatogenic” sequences in HCV-3, particularly phenylalanine (F) has been shown to be specifically associated with higher levels of lipid accumulation in cellular models *in vitro*[15]. All these findings are also supported by the observation that the degree of liver steatosis is directly related to the level of HCV replication as measured by serum HCV RNA, at least in the patients with HCV-3 infection in the absence of confounding metabolic causes of steatosis[16].

The third type of steatosis can be considered a “middle ground” between the first and the second one. Undoubtedly, this kind of steatosis is a combination of viral and metabolic factors and is associated with a direct interference of HCV core protein in the intracellular, post-receptorial pathways of insulin. This evidence, mostly found in the HCV genotype 1b patients, has convinced some authors to coin the term virus associated steato-hepatitis (VASH)[17,18]. Numerous studies have shown the involvement of HCV in steatosis. Some insights into the pathways of steato-hepatitis are defined by impaired lipid accumulation due to hepatic loss of adiponectin receptors, which play an important role in fatty acid accumulation by elevating the expression levels of the enzyme AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), fatty acid synthase, liver gluconeogenic enzyme and phosphoenol pyruvate carboxy kinase due to HCV infection[6,19-21]. Various studies have shown that steatosis is strongly correlated negatively with adiponectin in the patients with chronic HCV infection, and this finding suggests that adiponectin may have a role in modulating the progression of hepatic steatosis, fibrosis and inflammation[22]. The main objective of this review is to discuss the biological effect of adiponectin and its receptors in the progression of liver steatosis in the HCV-infected patients and the possible role of adiponectin as a therapeutic target for the treatment of fatty liver diseases.

**PHYSIOLOGICAL AND HEPATO-PROTECTIVE ROLE OF ADIPONECTIN**

Adipose tissue is an active endocrine organ which secretes a number of hormones involved in glucose/lipid metabolism. Adiponectin is a soluble matrix protein expressed exclusively by adipocytes and hepatocytes[23]. Recent studies have demonstrated adiponectin mRNA expression in liver after injury and skeletal muscle and that its expression and serum levels are reduced in humans and animals with obesity and insulin resistance[24,25].Adiponectin exists in three forms: low molecular weight trimers, medium molecular weight hexamers, and high molecular weight (HMW) multimers.

HMW adiponectin is thought to have more biological activity than other two forms. Human adiponectin gene is located at chromosome 3q27, and it codes for a 244 amino acid polypeptide. The primary sequence of adiponectin contains a signal peptide at the N-terminus, short hypervariable region and C-terminal half of the protein with a globular domain[26].

Adiponectin expression is reduced in obesity[27], insulin resistance and type 2 diabetes, and the plasma concentrations are inversely related to body weight, especially visceral adiposity[27-29]. Adiponectin is also inversely associated with other traditional cardiovascular risk factors, such as blood pressure, low-density lipoprotein cholesterol and triglyceride levels[30,31], and is positively related to high-density lipoprotein cholesterol (HDL-C) levels[32]. Recent research has indicated that adiponectin has anti-inflammatory properties, producing the anti-inflammatory mediator interleukin (IL)-10 in primary human monocytes, monocyte-derived macrophages and dendritic cells. In addition, adiponectin significantly impaired the production of the pro-inflammatory cytokine interferon-γ in human macrophages[33].

Adiponectin exerts its action via its two receptors, adiponectin receptor1 (Adipo R1) and Adipo R2. In mice, Adipo R1 is expressed abundantly in skeletal muscles, while Adipo R2 is considered as the primary transcript in liver. Adipo R1 and Adipo R2 are structurally related integral plasma membrane proteins with seven membrane-spanning domains. AdipoR1 possesses high affinity to the globular form of adiponectin and low affinity to full-length adiponectin, whereas Adipo R2 exhibits intermediate binding affinity to both the globular and the full-length adiponectin[34]. Adipo R1 and R2 mediate have increased AMPK activities, peroxisome proliferator-activated receptor alpha (PPAR-α) activities, fatty-acid oxidation and glucose uptake[35]. To confirm the physiological role of these receptors, Adipo R knockout mice have been generated, and in wild-type mice, adiponectin have lowered plasma glucose levels, whereas this effect of adiponectin has completely been abrogated in Adipo R1 and R2 double knockout mice[36,37].

It is known that adiponectin and its receptors have hepato-protective role in fatty liver diseases and steatosis development[35,38]. Adiponectin is believed to protect hepatocytes from triglyceride accumulation by increasing β-oxidation of free fatty acid and/or decreasing de novo free fatty acid production in hepatocytes[39]. Indeed, it has been shown that adiponectin stimulates AMPK in different tissues including liver. The precise mechanisms whereby adiponectin activates AMPK remain to be determined. However, phosphotyrosine interaction, PH domain and leucine zipper containing 1 (APPL1), an adaptor protein, appears to be the molecule that promotes the interaction between adiponectin and its receptors and the AMPK activation. The interaction between adiponectin receptor and APPL1 causes phosphorylation and activation of AMPK and AMPK phosphorylates ACC. The inhibition of ACC reduces lipid synthesis and increases fatty acid oxidation by blocking the production of malonyl-CoA, the allosteric inhibitor of carnitine palmitoyl transferase 1, which is the rate-limiting enzyme in fatty acid oxidation[40,41].

Moreover, AMPK downregulates the expression of sterol regulatory element-binding protein 1c, a transcription factor that regulates cholesterol and lipid synthesis[39,42]. Finally, adiponectin stimulates PPARα, a transcriptional factor controlling different genes involved in fat oxidation, such as acyl-CoA oxidase and long chain avyl-CoA synthetase[43] (Figure 1).

Recent data suggest that gut bacteria contribute to differences in body weight, insulin sensitivity, glucose metabolism and liver steatosis, in fact the imbalance of small intestinal bacterial overgrowth occurs in a large percentage of patients with chronic liver diseases, and has been associated with the severity of steatosis[44]. In particular some studies showed that the use of antibiotics to alter gut microbiota in obese mice reduces body weight, improves fasting glycaemia, glucose tolerance, and increases adiponectin levels. However, it is not clear how the gut microbiota plays a role in the production of adiponectin in adipose tissue, but this finding suggest that the gut microbiota could be a novel target for treating metabolic diseases, in fact high adiponectin levels enhance the insulin sensitivity and glycogen storage and decrease triglyceride accumulation[45,46].

**ADIPONECTIN AND LIVER STEATOSIS IN CHRONIC HEPATITIS C INFECTION**

Liver steatosis is a histological feature of CHC. CHC-related steatosis is chiefly virus-induced in HCV genotype 3 infection, while the host factors seem to play the major pathogenic role in HCV genotype non-3 infection. The evidence suggests that steatosis has an important role in the progression of liver fibrosis in CHC.

It has been demonstrated that adipocytokines are involved in the pathogenesis of non-alcoholic fatty liver disease, and the decreased plasma adiponectin levels are related to liver steatosis[47]. Hypoadiponectinemia has been implicated in the development of obesity-related morbidities such as dyslipidemia and cardiovascular diseases[48]. In addition, it is known that hypoadiponectinemia enhances hepatic steatosis, inflammation, fibrosis, and hepatocarcinogenesis in animal models of liver diseases[49]. Some studies have shown that steatosis is strongly correlated negatively with adiponectin in the patients with CHC infection[50-52]. These findings indicate a significant relationship between hepatic steatosis and adiponectin level. However, the role of adiponectin in HCV induced steatosis is still not completely understood, but the relationship between adiponectin low levels and liver steatosis is probably due to the ability of adiponectin to protect hepatocytes from triglyceride accumulation by increasing β-oxidation of free fatty acid and thus decreasing de novo free fatty acid production[40].

To clarify this point Durante-Mangoni *et al*[52] have found lower serum adiponectin levels and higher levels of tumour necrosis factor (TNF-α) in the chronic HCV patients. The higher tumour necrosis factor-α levels have particularly been observed in the patients with low adiponectin levels, and especially, in the patients infected whit HCV genotype-3. The extension of steatosis has inversely been correlated with adiponectin levels[52].

The substantial evidence in the available literature demonstrates that TNF-α inhibits adiponectin expression, and the decreased TNF-α level possibly contributes to the increased adiponectin level[53,54].The expression level of adiponectin in cultured adipocytes has significantly been reduced by co-culture with macrophages or upon the exposure to the conditioned media from macrophages, suggesting that macrophage secreted factors, possibly TNF-α, are responsible for repressing adiponectin production[55]. Moreover, Bruun *et al*[56] have shown that the increase in TNF-α and IL-6 serum levels and decrease in adiponectin serum levels may be involved in insulin resistance. During the HCV infection, the immune response against HCV releases reactive oxygen species (ROS) from sequestered phagocytes and activates Kupffer cells in the liver[57]. High levels of ROS can activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which is a transcription factor. As a consequence of NF-κB activation, the expression of a variety of cytokines is increased, including tumour necrosis factors (TNF-α and TNF-β), interleukins-1, 6 and interferon-γ[58].

TNF-α modulates adipocytes and induces changes and reductions in the production of cytokines, adiponectin and leptin[52,59]. Thus, the reduced levels of adiponectin may increase influx and synthesis of free fatty acids into the liver of the patients with HCV infection, generating liver steatosis (Figure 2)[35,60].

Jonsson *et al*[22] have studied 194 patients with chronic HCV to assess the relationship between serum adiponectin levels and hepatic steatosis. The authors have found that a decreased serum level of adiponectin is associated with steatosis only in males, so they have suggested that the role of adiponectin in the HCV infected patients might be linked to gender[22]. Various studies hypothesized a possible interaction between HCV core protein–PPARs–adiponectin. It has been reported that the HCV core protein impairs the expression of the PPAR-α which plays an important role as a target of adiponectin in lipid metabolism[61]. Undoubtedly, the administration of recombinant adiponectin has been shown to increase PPAR-α ligand activity and the administration of a PPAR-γ agonist is associated with a significant increase of adiponectin levels and reversal of steatosis[62,63].

In another study, Ashour *et al*[64] have demonstrated that the Egyptian patients with HCV genotype-4 infection and with steatosis have shown the reduced serum levels of adiponectin, with a significant inverse correlation between adiponectin level and steatosis grade, homeostatic model assessments index, body mass index and fibrosis stage. Moreover, they have proved that serum levels of adiponectin and leptin show no significant differences between males and females[64].

Corbetta *et al*[65] have hypothesized that hyperadiponectinemia might be sustained by down-regulation of hepatic Adipo Rs. In order to test this hypothesis, they have assessed the expression levels of Adipo R1 and Adipo R2 in CHC biopsies and have shown that Adipo R2 mRNA levels are similar in normal liver and HCV-infected liver biopsies, but the Adipo R1 mRNA expression levels have been reduced in HCV-infected liver biopsies compared with normal liver biopsies. This reduction was also confirmed at protein level[65].

Tiftikci *et al*[66] have shown that the leptin-to-adiponectin ratio is significantly reduced in the HCV chronic patients. The increased leptin concentration, corrected by reduced adiponectin values (leptin-to-adiponectin ratio), has been linked to the development of metabolic abnormalities[67], so the data obtained by Tiftikci about a reduced leptin-to-adiponectin ratio in the chronic HCV patients, lend a new support to the argument that protein adiponectin may be involved in the pathogenesis of liver injury in the patients with HCV infection.

In contrast with these results, Aksõz *et al*[68] have suggested that a decrease in the level of adiponectin may be associated with metabolic disorders, independent from chronic HCV infection. In fact, they have tried to investigate the effects of the virus in the patients without visceral obesity and metabolic disorders, so they have suggested that a decrease in the level of adiponectin may be associated with metabolic disorders in association with HCV infection, but HCV virus alone has not altered adiponectin serum concentration[68].

Different studies showed the influence of genetic factors in the development of HCV-induced liver steatosis. In this contest Valenti *et al*[69] have suggested that rs738409 single nucleotide polymorphism of patatin-like phospholipase domain-containing 3 (PNPLA3), encoding for a protein variant (I148M) that influences hepatic triglycerides accumulation and the susceptibility to fibrosis and steatosis, may represent a genetic determinant of serum adiponectin levels in non-alcoholic fatty liver disease (NAFLD) and CHC patients. In another work Valenti *et al*[70] showed that this genetic variant in CHC patients affects steatosis development, is independently associated with fibrosis and cirrhosis, and may influence response to antiviral treatment. Finally Nakamura *et al*[71] showed that in Japanese CHC patients there is no association between PNPLA3 rs738409 genotype, hepatic steatosis or liver fibrosis, suggesting that in HCV infection the mechanism of hepatic steatosis might be different from that of NAFLD.

**ADIPONECTIN AS THERAPEUTIC TARGET**

The biological effect of adiponectin and its receptors and their hepato-protective role in fatty liver diseases suggest that controlling the level of adiponectin receptors might be an important therapeutic target for the treatment of fatty liver diseases. There are no data on the potential therapeutic role of adiponectin in HCV chronic infection, but there are a lot of data showing that adiponectin is a therapeutic strategy for the treatment of insulin resistance, metabolic syndrome and steatosis that are common features of CHC, especially, in the patients infected with genotypes 3 and 1 virus. On the other hand, hepatic steatosis and IR reduce the probability of achieving a sustained virological response to pegylated interferon and ribavirin combination therapy[72], so reducing liver steatosis can be useful as a response to antiviral treatment in the patients with chronic HCV infection. Adiponectin replacement therapy is not yet available as a treatment option, but an alternative approach would be to identify and use the classes of the agents that can induce secretion or expression of adiponectin. In this context, some reports indicate that thiazolidinediones (TZDs) might up-regulate adiponectin, possibly, by increasing its rate of secretion[73,74], TZDs may up-regulate adiponectin by generating small adipocytes that express and secrete adiponectin and/or directly activating adiponectin gene transcription[75,76]. Other studies have shown that the inhibitors of the renin–angiotensin pathway, such as ACE inhibitor, increase serum adiponectin concentration, in fact, the blockers of the angiotensin pathway promote adipocyte differentiation[77].

Xu *et al*[78] have reported the identification of two structurally related natural compounds, astragaloside II and isoastragaloside I, from the medicinal herb *Radix Astragali*, that increase adiponectin secretion in primary adipocytes, without any effects on other adipokines. An alternative approach could be the design of the agents that serve as adiponectin mimetics. AMPK activators fall into such category because numerous adiponectin effects might be mediated via activation of AMPK. Moreover, the design of stable peptides or drugs, structurally and biologically simulating adiponectin production, could be another alternative[79].

*In vitro* studies have shown that adiponectin reduces free fatty acid-induced CD95/Fas expression and apoptosis of HepG2 hepatoma cells, which suggests that this hormone has a protective role with promising therapeutic implications, in fact, that the receptor mediated apoptosis is a prominent feature in various liver diseases, including HCV chronic infection[80]. Finally, it is known that adiponectin has anti-inflammatory activity and this can be a promising therapeutic implication in numerous diseases including HCV. The anti-inflammatory effects attributed to adiponectin include the inhibition of TNF-α production and activity, inhibition of nuclear factor kappaB activation and the induction of anti-inflammatory cytokines[81].

**CONCLUSION**

Steatosis development and CHC infection are clearly linked; about 20%–30% of chronic HCV infections are associated with hepatic steatosis. The biological mechanisms of the underlying steatosis occurrence and the progression to the liver disease are not entirely understood and are probably due to a number of factors: direct effect of the virus, genetic factors, metabolic syndrome and other unknown factors. The recent data suggest a significant link between hepatic steatosis and adiponectin low level. It is known that adiponectin and its receptors have hepato-protective role in fatty liver diseases and steatosis development. This relationship is probably due to the ability of adiponectin to increase β-oxidation of free fatty acid and to decrease de novo free fatty acid production. However, the role of adiponectin in HCV induced steatosis is still not completely understood. The biological effect, the hepato-protective role and the anti-inflammatory activity of adiponectin suggest that controlling the level of adiponectin, by increasing adiponectin production and using the drugs that structurally and biologically stimulate adiponectin, might be a potential therapeutic tool for the treatment of fatty liver diseases including steatosis induced by HCV chronic infection.

**REFERENCES**

1 **Björnsson E**, Angulo P. Hepatitis C and steatosis. *Arch Med Res* 2007; **38**: 621-627 [PMID: 17613353 DOI: 10.1016/j.arcmed.2006.09.001]

2 **Torti C**, Zazzi M, Abenavoli L, Trapasso F, Cesario F, Corigliano D, Cosco L, Costa C, Curia RL, De Rosa M, Foti G, Giraldi C, Leone R, Liberto MC, Lucchino D, Marascio N, Masciari R, Matera G, Pisani V, Serrao N, Surace L, Zicca E, Castelli F, Ciccozzi M, Puoti M, Focà A. Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology). *BMC Infect Dis* 2012; **12** Suppl 2: S9 [PMID: 23173812 DOI: 10.1186/1471-2334-12-S2-S9]

3 **Freeman AJ**, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 2001; **34**: 809-816 [PMID: 11584380]

4 **Abenavoli L**, Rouabhia S. Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or consequence? *Expert Rev Gastroenterol Hepatol* 2013; **7**: 295-297 [PMID: 23639086 DOI: 10.1586/egh.13.13]

5 **Abenavoli L**, Almasio PL. Chronic hepatitis C infection and insulin resistance: two best friends. *Expert Rev Anti Infect Ther* 2011; **9**: 555-558 [PMID: 21819320 DOI: 10.1586/eri.11.72]

6 **Khan M**, Jahan S, Khaliq S, Ijaz B, Ahmad W, Samreen B, Hassan S. Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. *Arch Virol* 2010; **155**: 1735-1753 [PMID: 20842391 DOI: 10.1007/s00705-010-0797-7]

7 **Roingeard P**. Hepatitis C virus diversity and hepatic steatosis. *J Viral Hepat* 2013; **20**: 77-84 [PMID: 23301542 DOI: 10.1111/jvh.12035]

8 **Solis-Herruzo JA**, Pérez-Carreras M, Rivas E, Fernández-Vázquez I, Garfia C, Bernardos E, Castellano G, Colina F. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. *Am J Gastroenterol* 2005; **100**: 1091-1098 [PMID: 15842583 DOI: 10.1111/j.1572-0241.2005.41059.x]

9 **Monto A**, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. *Hepatology* 2002; **36**: 729-736 [PMID: 12198667 DOI: 10.1053/jhep.2002.35064]

10 **Hézode C**, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. *J Viral Hepat* 2004; **11**: 455-458 [PMID: 15357652 DOI: 10.1111/j.1365-2893.2004.00528.x]

11 **Bochud PY**, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *J Hepatol* 2009; **51**: 655-666 [PMID: 19665246 DOI: 10.1016/j.jhep.2009.05.016]

12 **Barba G**, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Bréchot C. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. *Proc Natl Acad Sci USA* 1997; **94**: 1200-1205 [PMID: 9037030]

13 **Moriya K**, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. *J Gen Virol* 1997; **78**: 1527-1531 [PMID: 9225025]

14 **Rubbia-Brandt L**, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* 2000; **33**: 106-115 [PMID: 10905593 DOI: 10.1016/S0168-8278(00)80166-X]

15 **Hourioux C**, Patient R, Morin A, Blanchard E, Moreau A, Trassard S, Giraudeau B, Roingeard P. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. *Gut* 2007; **56**: 1302-1308 [PMID: 17213339]

16 **Adinolfi LE**, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 2001; **33**: 1358-1364 [PMID: 11391523]

17 **Koike K**, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. *J Gastroenterol* 2005; **40**: 329-336 [PMID: 15868369 DOI: 10.1007/s00535-005-1586-z]

18 **Masarone M**, La Mura V, Bruno S, Gaeta GB, Vecchione R, Carrino F, Moschella F, Torella R, Persico M. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. *J Viral Hepat* 2007; **14**: 714-720 [PMID: 17875006 DOI: 10.1111/j.1365-2893.2007.00861.x]

19 **Sheikh MY**, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. *Hepatology* 2008; **47**: 2127-2133 [PMID: 18446789 DOI: 10.1002/hep.22269]

20 **Perlemuter G**, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. *FASEB J* 2002; **16**: 185-194 [PMID: 11818366 DOI: 10.1096/fj.01-0396com]

21 **Leone TC**, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. *Proc Natl Acad Sci USA* 1999; **96**: 7473-7478 [PMID: 10377439]

22 **Jonsson JR**, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, Tilg H. Adiponectin and its receptors in patients with chronic hepatitis C. *J Hepatol* 2005; **43**: 929-936 [PMID: 16139921 DOI: 10.1016/j.jhep.2005.05.030]

23 **Maeda K**, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). *Biochem Biophys Res Commun* 1996; **221**: 286-289 [PMID: 8619847 DOI: 10.1006/bbrc.1996.0587]

24 **Waki H**, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. *J Biol Chem* 2003; **278**: 40352-40363 [PMID: 12878598 DOI: 10.1074/jbc.M300365200]

25 **Kaser S**, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. *Gut* 2005; **54**: 117-121 [PMID: 15591515 DOI: 10.1136/gut.2003.037010]

26 **Tsao TS**, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. *Eur J Pharmacol* 2002; **440**: 213-221 [PMID: 12007537 DOI: 10.1016/S0014-2999(02)01430-9]

27 **Sheng T**, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. *J Genet Genomics* 2008; **35**: 321-326 [PMID: 18571119 DOI: 10.1016/S1673-8527(08)60047-8]

28 **Arita Y**, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. *Biochem Biophys Res Commun* 2012; **425**: 560-564 [PMID: 22925674 DOI: 10.1016/j.bbrc.2012.08.024]

29 **Abenavoli L**. Adiponectin levels in nonalcoholic fatty liver disease. *Metabolism* 2011; **60**: e3 [PMID: 21917277 DOI: 10.1016/j.metabol.2011.08.002]

30 **Lautamäki R**, Rönnemaa T, Huupponen R, Lehtimäki T, Iozzo P, Airaksinen KE, Knuuti J, Nuutila P. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. *Metabolism* 2007; **56**: 881-886 [PMID: 17570246 DOI: 10.1016/j.metabol.2007.01.018]

31 **Kazumi T**, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. *Metabolism* 2004; **53**: 589-593 [PMID: 15131762 DOI: 10.1016/j.metabol.2003.12.008]

32 **Christou GA**, Tellis KC, Elisaf MC, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. *Hormones* (Athens) 2012; **11**: 178-188 [PMID: 22801564]

33 **Wolf AM**, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. *Biochem Biophys Res Commun* 2004; **323**: 630-635 [PMID: 15369797 DOI: 10.1016/j.bbrc.2004.08.145]

34 **Yamauchi T**, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature* 2003; **423**: 762-769 [PMID: 12802337 DOI: 10.1038/nature01705]

35 **Yamauchi T**, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med* 2002; **8**: 1288-1295 [PMID: 12368907 DOI: 10.1038/nm788]

36 **Tomas E**, Tsao TS, Saha AK, Murrey HE, Zhang Cc Cc, Itani SI, Lodish HF, Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. *Proc Natl Acad Sci USA* 2002; **99**: 16309-16313 [PMID: 12456889 DOI: 10.1073/pnas.222657499]

37 **Yamauchi T**, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. *Nat Med* 2007; **13**: 332-339 [PMID: 17268472 DOI: 10.1038/nm1557]

38 **Fruebis J**, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci USA* 2001; **98**: 2005-2010 [PMID: 11172066 DOI: 10.1073/pnas.98.4.2005]

39 **Yamauchi T**, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. *J Biol Chem* 2003; **278**: 2461-2468 [PMID: 12431986 DOI: 10.1074/jbc.M209033200]

40 **Kadowaki T**, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. *J Clin Invest* 2006; **116**: 1784-1792 [PMID: 16823476 DOI: 10.1172/JCI29126]

41 **Liu Q**, Gauthier MS, Sun L, Ruderman N, Lodish H. Activation of AMP-activated protein kinase signaling pathway by adiponectin and insulin in mouse adipocytes: requirement of acyl-CoA synthetases FATP1 and Acsl1 and association with an elevation in AMP/ATP ratio. *FASEB J* 2010; **24**: 4229-4239 [PMID: 20667975 DOI: 10.1096/fj.10-159723]

42 **Yamauchi T**, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. *Int J Obes* (Lond) 2008; **32** Suppl 7: S13-S18 [PMID: 19136982 DOI: 10.1038/ijo.2008.233]

43 **Tsuchida A**, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. *Diabetes* 2005; **54**: 3358-3370 [PMID: 16306350 DOI: 10.2337/diabetes.54.12.3358]

44 **Abenavoli L**, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. *Ann Hepatol* 2013; **12**: 357-363 [PMID: 23619251]

45 **Membrez M**, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Macé K, Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. *FASEB J* 2008; **22**: 2416-2426 [PMID: 18326786 DOI: 10.1096/fj.07-102723]

46 **Vrieze A**, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. *Diabetologia* 2010; **53**: 606-613 [PMID: 20101384 DOI: 10.1007/s00125-010-1662-7]

47 **Targher G**, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. *Clin Endocrinol* (Oxf) 2004; **61**: 700-703 [PMID: 15579183 DOI: 10.1111/j.1365-2265.2004.02151.x]

48 **Im JA**, Kim SH, Lee JW, Shim JY, Lee HR, Lee DC. Association between hypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults. *Metabolism* 2006; **55**: 1546-1550 [PMID: 17046559 DOI: 10.1016/j.metabol.2006.06.027]

49 **Asano T**, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, Ohnishi S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. *J Gastroenterol Hepatol* 2009; **24**: 1669-1676 [PMID: 19788607 DOI: 10.1111/j.1440-1746.2009.06039.x]

50 **Petit JM**, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, Verges B, Olsson NO, Gambert P, Hillon P. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. *J Clin Endocrinol Metab* 2005; **90**: 2240-2243 [PMID: 15644404 DOI: 10.1210/jc.2004-1266]

51 **Liu CJ**, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, Kao JH, Chen DS. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. *J Hepatol* 2005; **43**: 235-242 [PMID: 15964656 DOI: 10.1016/j.jhep.2005.02.044]

52 **Durante-Mangoni E**, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. *Aliment Pharmacol Ther* 2006; **24**: 1349-1357 [PMID: 17059516 DOI: 10.1111/j.1365-2036.2006.03114.x]

53 **Zhang L**, Sugiyama T, Murabayashi N, Umekawa T, Ma N, Kamimoto Y, Ogawa Y, Sagawa N. The inflammatory changes of adipose tissue in late pregnant mice. *J Mol Endocrinol* 2011; **47**: 157-165 [PMID: 21697073 DOI: 10.1530/JME-11-0030]

54 **Lira FS**, Rosa JC, Cunha CA, Ribeiro EB, do Nascimento CO, Oyama LM, Mota JF. Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation. *Lipids Health Dis* 2011; **10**: 37 [PMID: 21352586 DOI: 10.1186/1476-511X-10-37]

55 **Feng B**, Jiao P, Nie Y, Kim T, Jun D, van Rooijen N, Yang Z, Xu H. Clodronate liposomes improve metabolic profile and reduce visceral adipose macrophage content in diet-induced obese mice. *PLoS One* 2011; **6**: e24358 [PMID: 21931688 DOI: 10.1371/journal.pone.0024358]

56 **Bruun JM**, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. *Am J Physiol Endocrinol Metab* 2003; **285**: E527-E533 [PMID: 12736161]

57 **De Maria N**, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, Farinati F, Van Thiel DH, Floyd RA. Association between reactive oxygen species and disease activity in chronic hepatitis C. *Free Radic Biol Med* 1996; **21**: 291-295 [PMID: 8855439 DOI: 10.1016/0891-5849(96)00044-5]

58 **Wright E**, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. *Int J Clin Pract* 2006; **60**: 308-314 [PMID: 16494646 DOI: 10.1111/j.1368-5031.2006.00825.x]

59 **Neuman MG**, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, Trepo C, Bourliere M, Cameron RG, Cohen L, Morgan M, Schmilovitz-Weiss H, Ben-Ari Z. Cytokine--chemokine and apoptotic signatures in patients with hepatitis C. *Transl Res* 2007; **149**: 126-136 [PMID: 17320798 DOI: 10.1016/j.trsl.2006.11.002]

60 **Pajvani UB**, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. *J Biol Chem* 2003; **278**: 9073-9085 [PMID: 12496257 DOI: 10.1074/jbc.M207198200]

61 **Dharancy S**, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, Gambiez L, Mathurin P, Paris JC, Schoonjans K, Calmus Y, Pol S, Auwerx J, Desreumaux P. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. *Gastroenterology* 2005; **128**: 334-342 [PMID: 15685545 DOI: 10.1053/j.gastro.2004.11.016]

62 **Díez JJ**, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. *Eur J Endocrinol* 2003; **148**: 293-300 [PMID: 12611609 DOI: 10.1530/eje.0.1480293]

63 **Bajaj M**, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. *J Clin Endocrinol Metab* 2004; **89**: 200-206 [PMID: 14715850 DOI: 10.1210/jc.2003-031315]

64 **Ashour E**, Samy N, Sayed M, Imam A. The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4. *Clin Lab* 2010; **56**: 103-110 [PMID: 20476641]

65 **Corbetta S**, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, Beck-Peccoz P, Spada A. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. *Eur J Clin Invest* 2011; **41**: 898-905 [PMID: 21539538 DOI: 10.1111/j.1365-2362.2011.02498.x]

66 **Tiftikci A**, Atug O, Yilmaz Y, Eren F, Ozdemir FT, Yapali S, Ozdogan O, Celikel CA, Imeryuz N, Tozun N. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. *Arch Med Res* 2009; **40**: 294-298 [PMID: 19608019 DOI: 10.1016/j.arcmed.2009.04.008]

67 **Oda N**, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M. The ratio of leptin to adiponectin can be used as an index of insulin resistance. *Metabolism* 2008; **57**: 268-273 [PMID: 18191059 DOI: 10.1016/j.metabol.2007.09.011]

68 **Aksõz K**, Unsal B, Kirci A, Alper E, Buyraç Z, Aslan F, Cekiç C, Cengiz O, Ozcan Ari F, Akpinar Z. The relationship between chronic HCV infection and the level of plasma adiponectin. *Turk J Gastroenterol* 2008; **19**: 254-257 [PMID: 19119485]

69 **Valenti L**, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro G, Magni P, Fargion S. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. *BMC Gastroenterol* 2012; **12**: 111 [PMID: 22898488 DOI: 10.1186/1471-230X-12-111]

70 **Valenti L**, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. *Hepatology* 2011; **53**: 791-799 [PMID: 21319195 DOI: 10.1002/hep.24123]

71 **Nakamura M**, Kanda T, Nakamoto S, Miyamura T, Jiang X, Wu S, Yokosuka O. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. *PLoS One* 2013; **8**: e81312 [PMID: 24349054 DOI: 10.1371/journal.pone.0081312.]

72 **Agnello V**, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc Natl Acad Sci USA* 1999; **96**: 12766-12771 [PMID: 10535997 DOI: 10.1073/pnas.96.22.12766]

73 **Bodles AM**, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. *Am J Physiol Endocrinol Metab* 2006; **291**: E1100-E1105 [PMID: 16803857 DOI: 10.1152/ajpendo.00187.2006]

74 **Rasouli N**, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. *Am J Physiol Endocrinol Metab* 2006; **290**: E42-E46 [PMID: 16118250 DOI: 10.1152/ajpendo.00240.2005]

75 **Okuno A**, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. *J Clin Invest* 1998; **101**: 1354-1361 [PMID: 9502777 DOI: 10.1172/JCI1235.]

76 **Iwaki M**, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. *Diabetes* 2003; **52**: 1655-1663 [PMID: 12829629 DOI: 10.2337/diabetes.52.7.1655]

77 **Furuhashi M**, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. *Hypertension* 2003; **42**: 76-81 [PMID: 12796280 DOI: 10.1161/01.HYP.0000078490.59735.6E]

78 **Xu A**, Wang H, Hoo RL, Sweeney G, Vanhoutte PM, Wang Y, Wu D, Chu W, Qin G, Lam KS. Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. *Endocrinology* 2009; **150**: 625-633 [PMID: 18927219 DOI: 10.1210/en.2008-0999]

79 **Shetty S**, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. *Trends Pharmacol Sci* 2009; **30**: 234-239 [PMID: 19359049 DOI: 10.1016/j.tips.2009.02.004]

80 **Wedemeyer I**, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, Gerken G, Gieseler RK, Dienes HP, Canbay A. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. *J Hepatol* 2009; **50**: 140-149 [PMID: 19019483 DOI: 10.1016/j.jhep.2008.08.023]

81 **Palmer C**, Hampartzoumian T, Lloyd A, Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. *Hepatology* 2008; **48**: 374-384 [PMID: 18666256 DOI: 10.1002/hep.22387]

**P- Reviewer:** Chen EQ, Higuera-de la Tijera MDF, Invernizzi P, Kanda T, Lisotti A

**S- Editor:** Gong XM

**L- Editor:** **E- Editor:**

**Figure 1 Molecular pathways involved in anti-steatotic effect of adiponectin.** The interaction between adiponectin receptor and APPL1 causes activation of AMPK. AMPK inhibits ACC by phosphorylation. Inhibition of ACC increases fatty acid oxidation by blocking the production of malonyl-CoA, the allosteric inhibitor of carnitine palmitoyl transferase 1. AMPK downregulates the expression of SREBP1c, a transcription factor that regulates different genes involved in lipid synthesis. Finally, APPL1 stimulates PPARα, another transcriptional factor controlling genes involved in fat oxidation. APPL1: Phosphotyrosine interaction, PH domain and leucine zipper containing 1; AMPK: AMP-activated protein kinase; ACC: Acetyl-CoA carboxylase; SREBP1: Sterol regulatory element-binding protein 1; PPARα: Peroxisome proliferator-activated receptor alpha; CPT-1: Carnitine palmitoyl transferase 1.

**Figure 2 Liver steatosis induced by down-regulation of adiponectin and its receptor in chronic HCV infection.** HCV core protein associated with the mitochondria leads to increased ROS that activates NF-κB. As a consequence of NF-κB activation, expression of a variety of cytokines is increased, including TNF-α, IL-6 and INF-γ. TNF-α modulates adipocytes and induces reduction in the production of adiponectin and its receptor. Reduced levels of adiponectin induce the increase in the synthesis of free fatty acids and reduce β-oxidation, causing liver steatosis in the HCV chronic infected patients. HCV: Hepatitis C virus; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; IL: Interleukin; IFN-γ: Interferon-γ; TNF-α: Tumour necrosis factor α; ROS: Reactive oxygen species.